Sanofi, GSK to Supply Adjuvanted Covid-19 Vaccine to Canadian Government
September 22 2020 - 1:19PM
Dow Jones News
By Stephen Nakrosis
Sanofi and GlaxoSmithKline PLC on Tuesday said they signed
agreements which will see the companies supply up to 72 million
doses of an adjuvanted Covid-19 vaccine to the government of
Canada.
The deal will see the companies begin to supply the vaccine next
year.
Sanofi said it is leading the clinical development and
registration of the vaccine, and also said a Phase 1/2 study,
initiated on Sept. 3, will enroll 440 subjects.
The companies said they expect results in early December to
support the initiation of a Phase 3 study before year's end. "If
the data is sufficient for regulatory application, it is planned to
request regulatory approval in the first half of 2021," the
companies said.
"Both companies' global manufacturing networks will play a
pivotal role in the production of the Covid-19 vaccine for Canada,"
they said.
Thomas Triomphe, EVP and global head of Sanofi Pasteur, said "To
address a global health crisis of this magnitude, it takes
partnerships and we are grateful to Canada for its collaboration,
and to GSK for partnering with us to develop a safe and effective
vaccine."
Roger Connor, president of GSK Vaccines, said "GSK is proud to
be working in partnership with Sanofi to make this vaccine
available as soon as possible in Canada. Both companies have
significant R&D and manufacturing capability world-wide and are
already working hard to scale up production."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 22, 2020 13:04 ET (17:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024